Tag
A nonrandomized clinical trial demonstrates that incorporating pharmacists into primary care teams to manage opioid use disorder enhances feasibility, reduces care barriers, and maintains high acceptability among providers and patients.
Early initiation of methadone take-home dosing (5-24 weeks post-induction) reduces mortality and treatment discontinuation, surpassing benefits seen with no take-home dosing. Flexible dosing policies improve retention without increasing ove
Few US adults with alcohol or opioid use disorder reported addiction pharmacotherapy use in 2022-2023. Pharmacotherapy receipt was linked to increased healthcare utilization, underscoring the need for early outpatient intervention strategie
Patients with opioid use disorder (OUD) face higher postoperative complications, longer inpatient stays, and increased costs following hysterectomy. This review synthesizes clinical evidence and explores implications for surgical management
This study develops and compares predictive models incorporating claims and patient-reported data to forecast time to first opioid use disorder (OUD) or overdose (OD) among older adults with chronic pain on opioids, identifying key risk fac
A qualitative study across 12 Colorado hospitals found that an EHR-embedded OUD intervention improved awareness but still faced stigma, inconsistent messaging, limited addiction expertise, and workflow barriers to MOUD initiation.
A large cohort study found that health plan disenrollment after starting buprenorphine or naltrexone for opioid use disorder was linked to higher all-cause and overdose mortality, highlighting the importance of continuous coverage and treat
A clinical trial found that weekly extended-release buprenorphine significantly improves illicit opioid abstinence during pregnancy compared to sublingual forms, with fewer serious adverse events, offering a safer treatment option for opioi
The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction e
A geospatial analysis in Connecticut reveals that patients relying on public transit face travel times nearly four times longer than those with cars, with over 50% of areas lacking viable transit to methadone clinics, highlighting an urgent
The CLARO randomized clinical trial investigated whether a collaborative care model could improve outcomes for patients with opioid use disorder and co-occurring depression or PTSD. The study found no statistically significant advantages ov
This randomized clinical trial compares 100-mg and 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence among patients with high-frequency fentanyl
This randomized clinical trial compares 100-mg versus 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence rates among heavy fentanyl users, offeri
A pragmatic cluster randomized trial found that adding OUD-specific components to collaborative care in primary care clinics reduced days of opioid use more than collaborative care for mental health alone, without clear additional mental he
This nationwide cohort study reveals higher discontinuation rates of buprenorphine than methadone during pregnancy and up to one year postpartum, highlighting significant challenges in treatment retention for opioid use disorder in pregnant
A hospital-based addiction consult program lowered emergency department visits in opioid use disorder patients but did not reduce hospitalizations or mortality, highlighting the need for comprehensive care beyond hospital walls.
A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use d
A cluster randomized trial demonstrates that an electronic health record–integrated clinical decision support system increases naloxone prescriptions and opioid use disorder treatments in primary care but does not change diagnosis rates or
Overdose deaths from synthetic opioids alone in U.S. youth aged 15–24 surged 168% between 2018 and 2022, now representing one-third of all youth OD fatalities. Clinical vigilance, harm reduction, and targeted prevention are urgently needed.
